GLP-1 RA and SGLT2 Inhibitors: In Harmony for Organ Protection
- PMID: 37532423
- DOI: 10.1016/j.jacc.2023.06.005
GLP-1 RA and SGLT2 Inhibitors: In Harmony for Organ Protection
Keywords: ASCVD; GLP-1 RA; SGLT2 inhibitors; diabetes.
Conflict of interest statement
Funding Support and Author Disclosures Dr Aroda has been a consultant for Applied Therapeutics, Duke, Fractyl, Novo Nordisk, Pfizer, and Sanofi; has a spouse employed with Janssen; and has received research support (institutional contracts) from Applied Therapeutics/Medpace, Eli Lilly, Premier/Fractyl, Novo Nordisk, and Sanofi/Medpace. Dr Billings has been a consultant for Novo Nordisk, Eli Lilly, Sanofi, Xeris, and Bayer.
Comment on
-
GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes.J Am Coll Cardiol. 2023 Aug 8;82(6):517-525. doi: 10.1016/j.jacc.2023.05.048. J Am Coll Cardiol. 2023. PMID: 37532422
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
